Member Info for EarlofAim

Next week Major meeting with Bolivias ministers, YLB

Looks like few hedge funds are buying.....

Full year 2023 total revenue and other income of $17.5m compared to $6.2m in 2022

Full year 2023 Accrufer® revenue of $11.6m, approximately three times more than the prior year

21% increase in H2 Accrufer® average net selling price to $145/prescription

past is past

future looks good!!!!

Read Rns

$139m cash for wow!!!

rev 200% up from $6m to $17m

market over reacted!!

Looks like few hedge funds are buying.....

Full year 2023 total revenue and other income of $17.5m compared to $6.2m in 2022

Full year 2023 Accrufer® revenue of $11.6m, approximately three times more than the prior year

21% increase in H2 Accrufer® average net selling price to $145/prescription

London, UK, 21 February 2024: Shield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated specialty pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency (with or without anemia) today announces topline results for Q4 2023 and provides an unaudited trading update for the year ended 31 December 2023 ("FY23").

The operational progress made by Shield and its partnership with Viatris to create a new 100-person sales team, increase payer coverage, launch new brand campaigns, and ultimately deliver a tripling of U.S. Accrufer® prescriptions and revenues in 2023 - has been notable. In addition, recent market research reaffirms the unmet need in Accrufer's® target patient population, as healthcare professionals and patients continue to seek a well-tolerated and effective oral iron. During the fourth quarter of 2023, Shield strengthened its sales leadership and marketing organizations which will help drive more focused execution and prescription growth. The Company has also seen positive improvements in its gross-to-net in 2023 and expects that to accelerate further in 2024.

Business Metrics:

· Cash: $13.9m as of 31 December 2023

· Total 2023 revenue and other income: $17.5m, a 2.8x increase over FY22

o Accrufer® revenue: $11.6m, a 3.1x increase over FY22

o Ex-U.S. revenue: $1.5m

o Other income revenue including Viatris milestone payments: $4.4m

· U.S. Q4 2023 Revenue: $4.3m

· Average net selling price: c.$145/prescription in H2 2023, an increase of c.21% compared with H1 2023

· Total 2023 Prescriptions: c.77k, a 3.1x increase over FY22

12.75p just 4 months ago

wow!!

now 2.7p

Rsi at 12

chart not lying this is ridiculously cheap and Oversold.

management will learn fast

Sp should go 4p next few sessions as traders will pile ub

Chartist will be loading up here

way oversold

This should bounce back to 3.5p

way oversold

£17m revenue is some revenue

Mcap £19m

Barnacle

so 174 CDCs approved,

contract value per Centre is c£500k

thats a staggering £87M

Mcap only £7m

over 11 bagger to start off!!!

Not many cottoned on to FDBK potential for

put it simply, it's the Medical App equivalent to the likes of UBer, Just Eat and Deliberoo to Food industry!

that's the essence of Feedback plc and in a nutshell

even when UBer start up was valued 100s of millions.

NHS contract coming soon,

India as shown tremendous interest in FDBK, FDBK winning awards in India.

Ceo said India revenue is c£1Billion per year soon!

NHS contract will be in billions also

one to hold IMO

Looks like Investors /traders taking it up.

always buy when no one interested, so can buy loads without Spiking sp

another one I'm calling in FDBK

look at the bb posts, you'll be amazed by future revenues

Don't know why, but I like petroinvestor,

sometimes he does call out the scammers who posts nothing about the company, just one liner.

that's like blindly following.

Neil777 and Gordonbennett, and two fellas done well on He1 enormously

look at FDBK the Medical App equivalent to Uber, Just Eat and Deliberoo

all set up, now Waitn for NHS contracts and India

FDBK tech saves time and effort for NHS and medical professionals

worth a look

O dear...... why post Utter trash. no placing just yet

meanwhile

Fdbk

Is the medical App equivalent to Uber, Just Eat and Deliveroo.

Not many grasp its potential yet or the concept.

NHS already using o

in some hospitals look

I've not said anything On Here about Rsi kanners

???

Uber, Just eat and Deliberoo of medical industry

FDBK tech saves time and effort

NHS contract coming soon and India.

this is truly the UBer, Just Eat and Deliberoo of medical

If interested in the next UBer, just eat and Deliberoo of medical industry then look at FDBK

that's what's happening

Petroinvestor

I told you many times

whenever you come on my stocks it goes up fast,

you must be my lucky charm.

davey50 stopped posting on my shares as he don't like me making money.

it's about new trading style and Holding for gems

I didn't want to get too many Derampers to come on here, however it seems derampers don't care if its me or ria

or oppenheimer etc.......

Also India is which is around £1Billion per year.

huge potential here

If £500k is per hospital then its £430m

if £500k is per trust then £107m

thats only From NHS per year

add private hospitals over 200 and in the UK

huge numbers here